



US 20210253518A1

(19) **United States**(12) **Patent Application Publication**  
**NISHINO et al.**(10) **Pub. No.: US 2021/0253518 A1**(43) **Pub. Date: Aug. 19, 2021**(54) **KINASE INHIBITOR**(71) Applicant: **NISSAN CHEMICAL CORPORATION**, Tokyo (JP)(72) Inventors: **Taito NISHINO**, Shiraoka (JP);  
**Keiichi OTSUKA**, Shiraoka (JP);  
**Natsuki FUKASAWA**, Shiraoka (JP);  
**Hiroiyuki NAKAJIMA**, Shiraoka (JP);  
**Ayako AIHARA**, Shiraoka (JP)(73) Assignee: **NISSAN CHEMICAL CORPORATION**, Tokyo (JP)(21) Appl. No.: **16/973,337**(22) PCT Filed: **Jun. 6, 2019**(86) PCT No.: **PCT/JP2019/022536**

§ 371 (c)(1),

(2) Date: **Dec. 8, 2020**(30) **Foreign Application Priority Data**

Jun. 8, 2018 (JP) ..... 2018-110748


Jan. 30, 2019 (JP) ..... 2019-014898

**Publication Classification**(51) **Int. Cl.****C07C 281/14** (2006.01)**C07C 251/86** (2006.01)(52) **U.S. Cl.**CPC ..... **C07C 281/14** (2013.01); **C07B 2200/07** (2013.01); **C07C 251/86** (2013.01)

(57)

**ABSTRACT**

The present invention aims to provide a novel kinase inhibitor and the like, and a therapeutic agent for a disease, a drug discovery screening method and the like utilizing such inhibitor and the like. The compound represented by the following formula (I) and a salt thereof can inhibit plural kinases including LATS (particularly LATS2) which is the major kinase in the Hippo signal transduction pathway. In addition, diseases or tissue damage associated with failure of cellular proliferation can be treated. Therefore, the present invention is beneficial, for example, in the research field of cell functions and diseases, in which the Hippo signal transduction pathway is involved, and the like. Furthermore, it is beneficial in the medical field for the treatment of such diseases and the like.



(I)

wherein each symbol is as defined in the DESCRIPTION.

